This trial marks the first step taken by Actipulse Neuroscience to use a new method of neuromodulation to stop or slow Alzheimer's disease, an issue that fails to be solved by anything currently available on the market

The company aims to advance fast and effective development of an at-home neuromodulation device for Major Depressive Disorder treatment.

Small, smart, single-stage skull implanted DBS system can be implanted in under half the time of conventional implantations

Company wins funding from world-class venture capital sources for its disruptive noninvasive electrical neuromodulation therapy aimed at treating overactive bladder (OAB)

Company wins funding from world-class venture capital sources for its disruptive, noninvasive electrical neuromodulation therapy, aimed at treating overactive bladder (OAB)

CEO and Founder of Neurovations Honored as Patient Champion

Trial study at St. Thomas's Pain Management Centre shows dramatic effectiveness to treat chronic intractable pain

Makers of Buzzy® Needle Pain Relief to attend runDisney Health and Fitness Expo for product demonstrations and sales

Makers of Buzzy® Needle Pain relief today introduced a new noninvasive pain relief system for chronic and everyday pain sufferers.

IQ4I estimated by IQ4I Research that the Neuromodulation devices global market is expected to reach $9.3 billion by 2021.

Neuroscience R&D Technologies Conference to be held in Barcelona, Spain on 3 - 4 December 2015 will gather global neuroscience experts to discuss developments in brain imaging, animal models, neurogames, neuroinformatics and neuromodulation among others.

Soterix Medical Inc. announces a multidisciplinary study based at the University of Illinois Beckman Institute to determine if High-Definition tDCS (HD-tDCS) in conjunction with other interventions improves adaptive reasoning and fluid intelligence.

Soterix Medical, Inc. announces allowance of claims from the U.S. Patent Office for an application covering their system and method of non-invasive neuromodulation using the proprietary High-Definition transcranial Direct Current Stimulation platform

Cerbomed GmbH, an innovative medical device company concentrated on the development of new technologies for neuromodulation, has selected the CRO clinicalprojects international GmbH (CPI) to drive its multi-center European epilepsy trial.